<DOC>
	<DOCNO>NCT01979380</DOCNO>
	<brief_summary>To Evaluate safety tolerability KD101 single oral dose healthy male subject To Evaluate pharmacokinetic property KD101 single oral dose healthy male subject To Evaluate effect food bioavailability KD101 single oral dose healthy male subject</brief_summary>
	<brief_title>Phase I Clinical Trial Investigate Safety , Tolerability , Pharmacokinetics KD101 Healthy Male Subjects</brief_title>
	<detailed_description>This clinical trial dose block-randomized , double-blinded , placebo control , single ascend dose , food interaction study . AEs , PE , Vital sign , ECGs clinical lab test assess evaluate safety tolerability , blood urine collect evaluate pharmacokinetic parameter . This single ascending dose , food interaction study conduct KD101 dose 200 , 600 , 1000 1400 mg. After evaluate safety pharmacokinetic parameter single dose KD101 group 200mg , next high dose KD101 administer evaluate food interaction evaluate KD101 group 600mg .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<criteria>Subjects listen property clinical trial sign IRB approvedICF voluntary consent Male adult age 20 55 year screen Healthy volunteer whose BMI â‰¥ 18 Subjects adequate trial physical examination , lab examination , diagnosis physician Subjects clinically significant disease history ( liver , kidney , nervous , pulmonary , endocrinal , urinary , cardiovascular , musculoskeletal , mental system , blood , tumor ) diagnose within 1 month screen Subjects gastrointestinal disease ( Crohn 's disease , ulcer , acute/chronic pancreatitis ) affect absorption test drug gastrointestinal operation ( However , appendectomy , herniotomy induce acute appendicitis exclude ) Subjects / suspect follow history . [ myocardial infarction ( diagnosed cardiac enzyme and/or diagnostic ECG ) , cerebral infarction/stroke , arrhythmia need medical treatment , unstable angina , pulmonary hypertension ] Subjects positive result Human Immunodeficiency Virus , Hepatitis B virus , Hepatitis C virus screen Subjects allergy history ( ex . allergy aspirin , antibiotic , etc ) clinicallysignificant allergy Subjects whose systolic BP &lt; 85mmHg &gt; 145mmHg , diastolic BP &lt; 50mmHg &gt; 95mmHg , pulse &gt; 100/min 3 minuteseating position . ( BP remeasured twice leat 5 minuteinterval ) Subjects would take prescribed/oriental drug ( within 2 week first dose day ) OTC drug vitamines ( within 1 week first dose day ) Subjects drink 21 unit ( 1 unit = 10g pure alcohol ) quit drink alcohol clinical trial period Subjects ate follow food within 2 day first dose day quit follow food [ grapefruitcontain food , caffeincontain food ( coffee , green tea , black tea , soft drink , coffee milk , energy drink ) ] Subjects n't agree contraception Subjects n't agree quit smoke Subjects donate his/her blood within 2 month ( whole blood ) / 1 month ( apheresis ) take transfusion within 1 month Subjects participate another clinical trial within 3 month first dose day . ( The clinical trial completion day define last dosing day past clinical trial ) Subjects adequate trial lab examination another reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>KD101</keyword>
	<keyword>Anti-obesity Agents</keyword>
</DOC>